Literature DB >> 11774835

Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient.

D Thabut, V Thibault, Y Benhamou, B Bernard, C Aubron-Olivier, T Poynard, V Di Martino.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11774835     DOI: 10.1097/00002030-200112070-00020

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure.

Authors:  D Thabut; V Ratziu; B Bernard-Chabert; T Poynard; Y Benhamou; V Thibault
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

2.  Antiretroviral treatment interruption and loss to follow-up in two HIV cohorts in Australia and Asia: implications for 'test and treat' prevention strategy.

Authors:  Rebecca Guy; Handan Wand; Hamish McManus; Saphonn Vonthanak; Ian Woolley; Miwako Honda; Tim Read; Thira Sirisanthana; Julian Zhou; Andrew Carr
Journal:  AIDS Patient Care STDS       Date:  2013-12       Impact factor: 5.078

3.  Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients.

Authors:  Ya-Wen Yang; Chih-Yuan Lee; Rey-Heng Hu; Po-Huang Lee; Meng-Kun Tsai
Journal:  Clin Exp Nephrol       Date:  2013-04-19       Impact factor: 2.801

4.  Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.

Authors:  Gregory J Dore; Vicente Soriano; Jürgen Rockstroh; Bernd Kupfer; Ellen Tedaldi; Lars Peters; Jacqueline Neuhaus; Massimo Puoti; Marina B Klein; Amanda Mocroft; Bonaventura Clotet; Jens D Lundgren
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177

5.  Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.

Authors:  Eneida A Santos; Michel V F Sucupira; Juçara Arabe; Selma A Gomes
Journal:  BMC Infect Dis       Date:  2004-08-31       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.